All studies
RecruitingPHASE1, PHASE2INTERVENTIONAL

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Non-small cell lung cancer is sometimes driven by a faulty gene called ALK. This is known as ALK-positive lung cancer. Doctors usually treat it with targeted tablets, but the cancer can eventually find ways to resist these drugs. This trial is looking at an experimental targeted medicine called TRI-611. The main goals are to find the safest dose with the fewest side effects, and to see if the drug can help control or shrink tumours. The study has two stages. The first stage tests different dose levels to find the safest amount to give. The second stage tests how well TRI-611 works across different groups of patients, based on the cancer treatments they have had in the past. People in the trial take the medicine regularly, keep a diary, and visit the hospital for routine health and scan checks.

At a glance

Status
Recruiting
Phase
PHASE1, PHASE2
Sponsor
TRIANA Biomedicines, Inc.
Enrolment target
160
Start
11 Mar 2026
Estimated completion
30 Jan 2034

What is this study about?

Some types of non-small cell lung cancer have a specific change in their genes called an ALK rearrangement. This genetic change acts like an 'on switch', telling cancer cells to grow and spread. Standard care often involves targeted drugs that block this signal. While these drugs can work very well, the cancer can change over time and stop responding, leaving patients in need of new options.

TRI-611 is a new investigational targeted drug designed to block the ALK signal. Researchers hope it may work against lung cancer cells, including forms of the disease that have become resistant to other medicines. This trial is divided into two phases to carefully evaluate how TRI-611 behaves in the human body.

In the first part, doctors will give small, carefully monitored doses to a few patients. They will slowly increase the dose to find the best balance between safety and strength. In the second part, more patients will receive the chosen dose. This stage includes groups of people who have already tried several other ALK treatments, as well as a group who have never had targeted therapy before.

By taking part, participants help doctors learn whether TRI-611 is a safe and helpful treatment option for people living with ALK-positive lung cancer in the future.

Key takeaways

  • Tests a new targeted medicine (TRI-611) for ALK-positive non-small cell lung cancer.
  • Aims to find the safest dose and check how well it controls cancer growth.
  • Open to adults who have had previous targeted therapies, as well as those who have had none.
  • Requires frequent hospital visits in the first three months, followed by monthly check-ups.
  • Participation is entirely voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with ALK-positive non-small cell lung cancer that can be measured on a scan. Patients must have reasonably good general health, including satisfactory blood counts and kidney and liver function.

Because the trial has different groups, past treatment requirements vary. Some groups are looking for people who have already taken specific targeted medicines, such as lorlatinib. Another group is open to patients who have never had any ALK-targeted treatment before. Your doctor can help determine which group fits your treatment history.

You cannot take part if your cancer has certain other genetic changes that cause resistance, or if you have cancer spread to the brain or spine that is causing worsening symptoms or requires higher steroid doses. You also cannot join if you are currently receiving other cancer treatments, have had major surgery in the past four weeks, or have an allergy to the study drug.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have confirmed ALK-positive non-small cell lung cancer.
  3. My cancer can be measured on a scan.
  4. My general health and blood test results are suitable.
  5. I have not had major surgery in the last four weeks.
  6. Any cancer spread to my brain or spine is stable and not causing worsening symptoms.
Answer every question to see your result.

What does participation involve?

If you join, you will take the study drug TRI-611 on an ongoing basis. You will also be asked to keep a simple daily diary to write down when you take your medicine. In the first three months, you will need to visit the hospital clinic about seven times for close monitoring. After that, visits will typically happen once every four weeks (one 28-day cycle).

During clinic visits, the medical team will carry out standard checks, such as blood tests, physical examinations, and periodic imaging scans (like CT or MRI scans) to see how your tumour is responding. You can continue taking the study drug for as long as it is helping to keep your cancer stable and the side effects remain manageable. The total time you spend on the study depends entirely on how well the treatment works for you.

Potential risks and benefits

The possible benefit of taking part is that TRI-611 may help shrink your tumour or stop it from growing, although this cannot be guaranteed. You will also receive very close medical care and frequent monitoring from cancer specialists. However, because TRI-611 is an experimental drug, there is a risk of unexpected or uncomfortable side effects, and the treatment may not work for everyone. Taking part is completely voluntary. You are free to leave the trial at any point, and your regular NHS cancer care will continue as normal.

Locations (20)

  • UCSF
    Verified postcode
    San Francisco, United States· Recruiting
  • University of Colorado Cancer Center
    Verified postcode
    Aurora, United States· Recruiting
  • Massachusetts General Hospital
    Verified postcode
    Boston, United States· Recruiting
  • Dana Farber Cancer Center
    Verified postcode
    Boston, United States· Recruiting
  • Washington University Medical Center
    Verified postcode
    St Louis, United States· Recruiting
  • Memorial Sloan-Kettering Cancer Center
    Verified postcode
    New York, United States· Recruiting
  • Duke University
    Verified postcode
    Durham, United States· Recruiting
  • University of Cincinnati Cancer Center
    Verified postcode
    Cincinnati, United States· Recruiting
  • Taylor Cancer Research Center
    Verified postcode
    Maumee, United States· Recruiting
  • UPMC Hillman Cancer Center
    Verified postcode
    Pittsburgh, United States· Recruiting
  • SCRI Oncology Partners
    Verified postcode
    Nashville, United States· Recruiting
  • Oncology Consultants Research (P1 Trials)
    Verified postcode
    Houston, United States· Recruiting

Common questions

What does ALK-positive mean?

It means your lung cancer cells have an altered version of the ALK gene. This gene change produces an abnormal protein that causes the cancer to grow.

Is TRI-611 a chemotherapy drug?

No. TRI-611 is a targeted therapy designed to block specific signals in cancer cells, which works differently from traditional chemotherapy.

Will I have to pay for the trial medicine?

No. In UK clinical trials, the investigational medicine and all study-related tests are provided free of charge.

Can I leave the trial if I change my mind?

Yes. You can leave the study at any time and for any reason, without it affecting your relationship with your healthcare team or your future care.

What happens if my cancer gets worse during the study?

If your scans show that the cancer is growing, or if the side effects become too difficult, the study medicine will be stopped and your doctor will discuss other treatment options with you.

How to find out more

TRIANA Clinical Trials

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.